What is Neos Therapeutics Debt-to-Equity?
Neos Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $27.49 Mil. Neos Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $16.46 Mil. Neos Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2020 was $-20.55 Mil.
Neos Therapeutics's debt to equity for the quarter that ended in Sep. 2020 was -2.14.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Neos Therapeutics's Debt-to-Equity or its related term are showing as below:
NEOS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -41.03 Med: 0.51 Max: 49.85
Current: -2.14
During the past 7 years, the highest Debt-to-Equity Ratio of Neos Therapeutics was 49.85. The lowest was -41.03. And the median was 0.51.
Neos Therapeutics Debt-to-Equity Historical Data
The historical data trend for Neos Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neos Therapeutics Debt-to-Equity Chart
|
Neos Therapeutics Annual Data
|
|
Trend |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
0.44 |
-41.03 |
6.69 |
6.60 |
-7.97 |
|
Neos Therapeutics Quarterly Data
|
|
Dec15 |
Mar16 |
Jun16 |
Sep16 |
Dec16 |
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-16.17 |
-7.97 |
-4.35 |
-2.56 |
-2.14 |
Competitive Comparison of Neos Therapeutics's Debt-to-Equity
For the Drug Manufacturers - Specialty & Generic subindustry, Neos Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neos Therapeutics's Debt-to-Equity Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neos Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Neos Therapeutics's Debt-to-Equity falls into.
Neos Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Neos Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as
Neos Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neos Therapeutics (Neos Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
2940 N. Highway 360, Grand Prairie, TX, USA, 75050
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.
Executives
| Alan L Heller |
director |
BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015 |
| Gregory J Robitaille |
director |
|
| John P. Schmid |
director |
6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
| Beth Hecht |
director |
C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050 |
| Linda M Szyper |
director |
C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050 |
| Bryant Fong |
director |
2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123 |
| Robinson James A. Jr. |
director |
852 WINTER STREET, WALTHAM MA 02451 |
| Gerald W. Mclaughlin |
director, officer: Chief Executive Officer |
227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
| Richard I Eisenstadt |
officer: Chief Financial Officer |
4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
| John M Limongelli |
officer: SVP & General Counsel |
700 PENNSYLVANIA DRIVE, EXTON PA 19341 |
| Thomas P Mcdonnell |
officer: Chief Commercial Officer |
C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050 |
| Vipin K Garg |
officer: Chief Executive Officer |
4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
| Dorothy Engelking |
officer: VP, Regulatory Affairs |
C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050 |
| Paul R Edick |
director |
C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010 |
| Juergen Martens |
officer: Chief Tech/Operations Officer |
28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
Neos Therapeutics (Neos Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NEOS has been successfully added to your